Imatinib Mesylate (Gleevec®, STI571) in Combination With Docetaxel (Taxotere) for the Treatment of Advanced, Platinum-Refractory Ovarian Cancer and Primary Peritoneal Carcinomatosis: Hoosier Oncology Group GYN03-62

For full description, see www.clinicaltrials.gov.

Abstracts/Posters/Presentations:

• Daniela Matei, Robert E. Emerson, Nancy Menning, Jeanne Schilder, John McClean, Greg Sutton, Doyle Stephens, Misty Witherite, Charles Whalen, David H. Moore. Clinical Activity of Imatinib Mesylate (Gleevec) In Combination with Docetaxel In Patients With Advanced, Platinum-Resistant Ovarian Cancer Or Primary Peritoneal Carcinomatosis: Hoosier Oncology Group GYN03-62. Accepted to the ASCO Annual Meeting June 2-6, 2006, Atlanta, GA

Manuscripts/Articles:

• Matei D, Emerson RE, Schilder J, Menning N, Baldridge LA, Johnson CS, Breen T, McClean J, Stephens D, Whalen C, Sutton G. Imatinib Mesylate in Combination with Docetaxel for the Treatment of Advanced, Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinomatosis, a Hoosier Oncology Group Trial GYN06-111. CANCER, 2008 Aug 15;113(4):723-32. PMID: 18618737. See abstract.